hypothalamic

Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients withAcquired Hypothalamic ObesityRhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients withAcquired Hypothalamic Obesity

Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients withAcquired Hypothalamic Obesity

Company to host conference call on April 7 at 8 a.m. ET April 06, 2025 12:00 ET  | Source: Rhythm…

4 weeks ago